Edgar Filing: Vanda Pharmaceuticals Inc.

VANDA PHARMACEUTICALS INC.

Dated: April 10, 2014

/s/ James P. Kelly

James P. Kelly

Senior Vice President, Chief Financial Officer,

Secretary, and Treasurer

8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 9, 2014

VANDA PHARMACEUTICALS INC.

(Exact Name of Registrant as Specified in Charter)


Delaware	001-34186	03-0491827
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2200 Pennsylvania Avenue NW Suite 300E Washington, DC		20037
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (202) 734-3400

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 DFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.

OTHER EVENTS.

On April 9, 2014, Vanda Pharmaceuticals Inc. issued a press release announcing, among other things, that HETLIOZ™ has become available for shipment to pharmacies in the United States. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01.

FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.


Exhibit No.		Description

99.1		Press Release of Vanda Pharmaceuticals Inc. dated April 9, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.